Health Care • Biotechnology: Pharmaceutical Preparations
$1.02 ▲ +0.01
(+0.99%)
MKT CAP: $10.9M • VOL: 60.8K
52W L $1 52W H $5
ROARABLE / RQD
E • 29/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$1
MEDIAN
$1
MEAN
$1
HIGH
$1
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LSTA TAPE
LSTA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1.23 | $1.17 | 2025-02-14 | $0.93 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1.29 | $1.20 | 2025-02-06 | $0.96 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1.16 | $1.12 | 2025-01-29 | $0.98 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $1.04 | — | 2025-01-17 | $1.00 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $0.90 | $0.97 | 2025-01-09 | $0.91 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1.21 | $1.06 | 2024-12-18 | $0.89 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $0.99 | $1.03 | 2024-12-04 | $0.95 | -4.3% | 48% | C |